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Abstract
Background: Bauhinia racemosa Lam. (BR) has been used widely for the treatment of diabetes since ancient times.
Along with its medicinal importance; the tree having great traditional value in India. The protocol was performed using
Wistar rats to determine the effect of petroleum ether extract of BR leaves on blood glucose level, adipose tissue and lipid
profile. The study was further evaluted to determine insulin level, glucose tolerance, food and water intake of the animals.
Methods: Wistar rats of both sexes were selected for the study. Diabetes was induced by intraperitoneal injection of
streptozotocin (STZ) 45 mg/kg. Animals were divided into five groups namely control group, diabetic group, reference
group (glibenclamide) and two test groups BR-1 (250 mg/kg extract) and BR-2 (500 mg/kg) each group containing 6
animals. Daily dosing was performed for 28 days and feed and water consumption was observed regularly at the end
of the study.
Results: The main finding of the study for the test extract was that the petroleum ether extract of BR leaves prevented
a rise in blood glucose level in STZ induced diabetic animal. Furthermore, extract showed significant antiadipogenic
and antihyperlipidemic effect. It improved lipid profile by decreasing the levels of serum triglycerides, total cholesterol,
low-density lipoprotein (LDL) and increasing high-density lipoprotein (HDL) cholesterol. Extract exhibited the
concentration-dependent inhibitory effect with an IC50 value of 660.26 μg/ml.
Conclusions: It can be concluded from the study that BR extract posses signigicant antidiabetic activity by reducing
blood glucose level of diabetic rats. It also normalized adipose tissues and lipid level. Due to its potential, it may be an
effective drug for treatment of diabetes and related complications like obesity and dyslipidemia.
Keywords: Adipocyte differentiation assay, Oral glucose tolerance test, Diabetes, Hyperlipidemia, Obesity
Background
Diabetes mellitus is a metabolic disorder characterized by
abnormal carbohydrate, protein and fat metabolism due to
deficient insulin action on target tissues which results in
hyperglycemia [1]. Diabetes mainly is of two types Type-1
and Type-2 diabetes i.e. insulin dependent diabetes melli-
tus (IDDM) and non-insulin dependent diabetes mellitus
(NIDDM) respectively [2, 3]. According to International
Federation of Diabetes report it is estimated that 387
million people have been suffering from diabetes till 2014,
in which 90% cases of type-2 diabetes. The numbers of
diabetic people are expected to rise to 592 million by 2035
[4]. Increase incidence of visceral obesity is closely associ-
ated with the risk of diabetes mainly Type-2 diabetes [5].
There is a pronounced correlation between an increased
quantity of visceral fat, metabolic disorder and heart
related diseases [6].
Bauhinia racemosa Lam. (BR) belongs to the family
Caesalpiniaceae, popularly known as ‘Sonpatti’ in India.
Its leaves are simple, bilobed, and alternate; stipules
small, caducous, petiole 10–33 mm long, slender, pubes-
cent, swollen at the base and at the tip. Poor and harsh
climate is favorable for its growth of rare medicinal tree.
The tree is widely distributed throughout India, Srilanka,
Ceylon, China and Timor [7]. The deciduous tree is
propagated easily from seed. Almost each & every part
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of this tree has some medicinal values. The tree has
small, creamy white or yellow colored flowers in axillary
or terminal racemes. The flowers of BR are laxative &
seeds are anti-bacterial [8] and [9]. BR commonly used
in the treatment of diabetes, however, its other species
like Bauhinia vahlii, Bauhinia variegata, Bauhinia pur-
purea, Bauhinia tomentosa has been used as antidiar-
rhoeal, antispasmodic, anti-inflammatory, carminative,
vermicidal and hepatoprotective activity [10, 11]. The
tree yields a useful gum & fibers, bark is used for dyeing.
Juice of BR which is extracted from the tender shoots is
mixed with mother’s milk and used to clean and cool
eyes. The bark fiber is used to make ropes to make lad-
ders and to tie cows [12].
The phytochemistry of Bahuinia revealed the presence
of a new tetracyclic lupeol, betulin, β-sitosterol, and
tetracyclic 2, 2-dimethyl chroman isolated from the
roots [13]. Stem bark revealed the presence of alkaloids,
glycosides, carbohydrates, saponins, flavonoids, triterpe-
noids (ß-amyrin), anthroqunonine, steroid (ß-sitosterol)
stilbene (resveratrol) [14] and [15]. It has been reported
that different plant isolates possess insulin releasing,
pancreatic beta cells re-generating and fighting the insu-
lin resistance problems.
Methods
Collection, authentication and extraction
Leaves of BR were collected from forest of Ambikapur
(23.1200° N, 83.2000° E) district of Chhattisgarh in the
month of December 2014 authenticated by Dr. N. K.
Satti, Department of Natural Products, Institute of
Integrative Medicine, Jammu, and leaves were deposited
in the herbarium of the Institute. 1 kg leaves of BR were
extracted with petroleum ether by cold percolation at
b.p. 40–60 °C and percentage yield was found to be
6.42%. The extract was dried with the help of evaporator
(Buchi, USA) under reduced pressure, temperature (37 –
40 °C). Dried extract was placed in an airtight container
and further used for studies as antidiabetic, antiadipo-
genic, and hypolipidemic studies [16].
Phytochemical screening
The petroleum ether extract of BR leaves was subjected
to different chemical tests separately for identification of
various active constituents employing standard protocols
recommended by WHO [17].
Experimental animals
Wistar rats were selected for the study weighing 170–
190 g. Experimental protocol was prepared to take the
minimum number of animals for in-vivo and acute
toxicity study and selected animals were approved by the
Institutional Animal Ethical Committee (IAEC reg no-
68/99/CPCSEA/reg) of Indian Institute of Integrative
Medicine (IIIM), CSIR, Jammu. The animals kept in the
arrangement of 12 h light and 12 h dark conditions with
temperature maintained at 22 ± 2 °C and humidity 47 ±
65%. Pelleted diet was used for animals feeding through-
out the study and water ad libitum. Animals were divided
into five different groups as normal control (NC), diabetic
control (DC), reference group (RG), test group-1 (BR-1)
(250 mg/kg), test group-2 (BR-2) (500 mg/kg) each group
containing six animals.
Cell line
3T3-L1 cell line was used for evaluating in vitro antiadi-
pogenic activity which was procured from National
Centre for Cell Science (NCCS), Pune, India.
Chemicals used
Dexamethasone, Dimethyl sulfoxide (DMSO), Dulbecco’s
modified Eagle’s medium (DMEM), Fetal bovine serum
(FBS), Gentamycin, Insulin, Penicillin, Phosphate Buffer
Saline (PBS), Roswell Park Memorial Institute medium
(RPMI), Streptomycin, Trypsin, Sodium Pyruvate were
purchased from Sigma Chem. Co., USA. Other chemicals
are Cholesterol (Qualigens fine chem., glaxo India Ltd.),
Ethylenediamine tetraacetic acid, disodium salt (EDTA)
(HiMedia Laboratories Pvt. Ltd., Mumbai), Formaldehyde
(Qualigens fine chem., glaxo India Ltd.), 3-isobutyl-1-
methylxanthine (IBMX), Isopropyl alcohol (Sisco Research
Laboratories. Pvt. Ltd., Mumbai), Sodium bicarbonate
(NaHCO3) (HiMedia Laboratories Pvt. Ltd., Mumbai), Oil
Red O Dye, Blood glucose, Triglyceride, Total Cholesterol,
FFA estimation kits (Siemens Medical Solutions Diagnos-
tics Ltd., Baroda, Gujarat, India), Rat Insulin ELISA kit
(Mercodia, Sweden), Simavastatin, Glibenclamide
(Nicholas Piramal Research Limited Mumbai).
Pharmacological screening methods
In-vitro methods
In-vitro cytotoxicity assay 3T3-L1 cell line was assayed
by Neutral Red Assay in order to determine in vitro tox-
icity of petroleum ether extract of BR-1 and BR-2. The
cell line was cultured in DMEM complete media using
150 cm2 culture flasks with temperature maintained at
37 °C allowing 5% CO2 and relative humidity more than
90%. Test extract was diluted appropriately in DMEM
medium, were added to the cells and again incubated for
48 h. Cells viability was determined using Neutral Red
Assay procedure. Briefly, cells were seeded 2.5 × 104
cells/well at temperature maintained 37 °C and allowed
to grow undistributed for 24 h then cell counts were
made by using the Trypan Blue exclusion method to de-
termine viability of cells [18]. Cell containing extract was
exposed in the presence and absence of UV light. Cell
observed under UV light was labelled as light extract
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(LE) however dark extract (DE) was named when extract
observed in dark. After incubating with samples, the
cells were washed with saline and incubated for 90 min
with the medium containing Neutral Red (166 ug/ml).
On addition of isopranol (0.33% HCl) to lyses the cells;
as a result, the incorporated dye was liberated from the
viable cells. The absorbance was measured at 540 nm on
a Microplate Reader (Molecular Devices, SPECTRA-
MAX plus 384). All the assays were performed in tripli-
cate. The above procedure was performed as per our
previous work [18]. Viability of cell was calculated by
the using the formula below at 540 nm absorbance in
light and dark conditions.
% Viability ¼ ODsampleX100
ODnegativecontrol
Here, OD (Optical Density/Absorbance), OD sample =
absorbance of cell at different dose, OD negative control =
absorbance of 100% viable cell
Dose response curve for the toxicity studies Dose
response curve of BR extract for 3T3-L1 cell line is shown
in Fig. 1. Extract exhibited concentration-dependent inhibi-
tory effect with an IC50 value of 660.26 μg/ml.
Adipocyte Differentiation assay Differentiation was
induced by subculture and seeding of preadipocyte cell
line. Cells were harvested from 25 mm tissue culture
flask when the cells around 70 to 80% confluent by using
trypsinization. 96 well plate (2 x 103 cells/well cell dens-
ity and volume of media per well 100 μl) tissue cul-
ture vessels was used for seeding of cells in complete
media. Cells were growing for 2 days to reach 100%
confluency. Cells were kept for another 48 h in this
state, to arrest the cell division, then treated with adi-
pocyte differentiation media (1 μM Dexamethasone,
0.5 mM 3-Isobutyl-1-methylxanthine, 10 μg/ml Insu-
lin and complete media). Cells were feeded with adi-
pocyte differentiation media after post confluency.
Test extract was evaluated in different dose of 50,
100 and 200 μg/ml at day 0 for adipocyte differenti-
ation assay and kept the cells for 96 h in this state.
All the media were discarded after 96 h by gentle
pipetting. Cells were easily detachable from plate at
this stage. At 4th day adipocyte differentiation media
Fig. 1 Dose response curve of BR extract for 3T3-L1 cell line. Values are expressed as mean ± SEM (n = 6). Dose response curve of the extract re-
vealed poor discrimination at 25 μg/ml and showed greater sensitivity at 200 μg/ml. Ceiling effect observed at 1000 μg/ml where no more in-
crease in the response is seen with further increase in the dose. Extract exhibited the inhibitory effect with an IC50 value of 660.26 μg/ml
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was added by subsequent changes in every 2 days.
Lipid droplets were visible inside the cells after 8th
day and droplets enlarges at around the 14th day.
After day 8, water was removed and kept it in dry.
Elute oil Red O by adding 100% isopropanol
incubated for 10 min OD measurement at 540 nm in
spectrophotometer [19]. Extract was evaluated at both
light and dark conditions at 540 nm absorbance and
determine percentage cell inhibition using the formula
below:




Acute toxicity study The acute toxicity study was
carried out on male Wistar rats weighing 150–200 g by
administering extract orally at one of the levels (150,
500, 1000, 2000 mg/kg) once only. The dose that shows
toxicity signs/morality is the toxic dose and 1/10th of
this toxic dose is considered for therapeutic exploration
[20]. Toxicity study of extracts was performed as per
OECD guideline No.423.
Eighteen hours fasted Rat model Male Wistar rats, six
animals in each group were fasted overnight. Blood
glucose determination was done initially at 0 h prior to
drug treatment and finally at 3 h after drug treatment
has over. Animals were divided into four groups, namely
normal control 1% v/v Tween 80 (10 ml/kg), reference
group (glibenclamide; 5.0 mg/kg), test group; BR-1
(250 mg/kg extract) and BR-2 (500 mg/kg extract).
Oral Glucose Tolerance Test (OGTT) Oral glucose
tolerance test was performed on overnight fasted male
Wistar rats. Animals were divided into different groups
as normal control (untreated), glucose primed control,
reference group (glucose primed + glibenclamide), test
groups (glucose primed + test extract). Glucose was
given in the dose of 1.5 g/kg of 10% solution to all
groups except normal control. Estimation of blood was
done at 0 min (prior to any treatment), 30 min and
90 min [21].
Induction of diabetes in rats Diabetes was induced by
single intraperitoneal injection of freshly prepared STZ
(65 mg/kg body weight) in 0.1 M citrate buffer (pH 4.5)
in a volume of 1 ml/kg body weight. Nicotinamide was
given in the dose of 110 mg/kg prior to induction of
diabetes to reduce the beta cytotoxic effect of streptozo-
tocin. Diabetes was established in these STZ treated rats
over a period of 4 days. The control animals were
treated with citrate buffer (pH 4.5). After 4 days blood
was collected from the retro-orbital route and the
plasma glucose level of each rat was determined. Ani-
mals were evaluate by using glucometer and considered
diabetic when fasting blood glucose (FSG) level higher
than 250 mg/dL [22].
Treatment Protocol for STZ induced diabetic rats
model The diabetic rats were divided randomly into five
different groups, each containing six animals. Normal
and Diabetic control animal groups received 1% v/v
Tween 80 (1 ml/kg p.o.), Reference group received
glibenclamide 5.0 mg/kg p.o. and extract of BR was
given in the doses of 250 and 500 mg/kg in 1% v/v of
Tween 80 (1 ml/kg p.o.) for a period of 28 days to differ-
ent treatment groups. The blood sample was collected
on 0, 7, 14, 21 and 28 days.
Blood glucose Blood glucose was estimated by glucose
oxidase/peroxidase (GOD/POD) method using a com-
mercially available enzymatic kit from Siemens Medical
Solutions Diagnostics Ltd., Baroda and Gujarat, India.
The absorbance of the test samples and reference was
measured against blank at 505 nm spectrophotometrically.
The concentration of the glucose was calculated using the
following formula:
Concentrationof glucose ¼ Opticaldensity of test
Opticaldensity of standard mgdl
  100
Insulin ELISA The principle of the Rat Insulin ELISA is
based on a solid phase two-site enzyme immune assay.
It is based on the direct Sandwich technique in which
two monoclonal antibodies are directed against separate
antigenic determinants on the insulin molecule.
During incubation insulin in the sample reacted with
peroxidase-conjugated anti-insulin antibodies and
bound to microtitration well. A simple washing step
removes the unbound enzyme labeled antibody. The
bound conjugate was detected by reaction with 3, 3β,
5, 5β-tetramethylbenzidine. The reaction was stopped
by adding acid to give a colorimetric endpoint that
was read spectrophotometrically [23].
Lipid profile Different lipid parameters in blood like
Triglycerides (TGs), Total Cholesterol (TC), low density
lipoprotein (LDL), high density lipoprotein (HDL) were
estimated using suitable assay procedures. Triglycerides
are the chemical form in which most fat exists in food
as well as in the body. Triglycerides (TGs) were deter-
mined by enzymatic colorimetric method (Adipogenesis
assay kit). Triglyceride concentration in the sample was
measured at 546 nm. The determination of serum
cholesterol was considered to be significant in Diabetes
Mellitus and various other diseases. Total cholesterol
(TC) was estimated by the enzymatic method as
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described by [24]. HDL and LDL were estimated using
commercial kits procured from Bayer Diagnostics &
Siemens Healthcare, India with the aid of a clinical
chemistry analyser Chem-7 (Erba, Manheim, Germany).
Statistical analysis All values were expressed as Mean
± SEM. The results were analyzed statistically using two
way analysis of variance (ANOVA) followed by Bonferroni
post-tests to calculate the level of significance. Values are
expressed as mean ± SEM (Number of animals, n = 6); sig-
nificantly different at *p < 0.05, **p < 0.01, ***p < 0.001,
when compared with diabetic control group.
Result
Phytochemical screening
The preliminary phytochemical screening of BR petroleum
ether extract revealed the presence of saponins, sterols,
carbohydrates, flavonoids, triterpenes and proteins.
In-vitro methods
In vitro toxicity of BR extract on 3T3-L1 cell lines
The BR extract was exposed to two different conditions
of dark (DE) and light (LE) conditions. In vitro toxicity
of BR extract was evaluated on 3T3-L1 cell lines by
Neutral Red assay at different concentrations of 200,
100, 50 and 25 μg/ml; all the concentration showed
more than 75% viability. However the extract exposed in
dark condition exhibited more viability of cells at different
concentrations as compared to light condition (Table 1).
Antiadipogenic activity of BR extract on 3T3-L1 cell line
BR extract showed significant antiadipogenic activity in
both dark and light conditions. However the percentage in-
hibition of adipocyte cells by the extract in dark condition
at the concentration 200 μg/ml was found to be 41.66%,
which was lesser than the standard drug simvastatin
(51.83%). The antiadipogenic effect of the BR extract on
3T3-L1 cell Line is shown in Table 2.
In-vivo experimental methods
Acute toxicity study
An acute toxicity study revealed that BR extract did not
produce any toxic sign and symptoms even no any
mortality when administered per orally to rats at a dose
up to 2000 mg/kg. According to the dose safety level
upto 2000 mg/kg two doses of BR extract, i.e. 250 and
500 mg/kg were selected for in-vivo antidiabetic study.
Effect of BR extract on eighteen hours fasted Rat model
The BR extract was found effective in reducing blood glu-
cose level on eighteen hour fasted rat model. However re-
duction in blood glucose level by the extract BR-2 was
found to be 58.8 mg/dl, which was nearly equal to refer-
ence drug glibenclamide (51.4 mg/dl) after 3 h. The results
of reduction in blood glucose level by BR extracts have
been summarized in Fig. 2.
Effect of BR extract on Oral Glucose Tolerance Test (OGTT)
In this model blood glucose level was evaluated on three
time points, i.e. 0 min, 30 min and 90 min in glucose
primed rats. Reduction in glucose level by BR-2 was
significant at 90 min i.e. 115.65 mg/dl, which was closer
to 90.44 mg/dl of reference group. Glucose level was
increased at 30 min in all treatment groups, but it was
reduced in a significant manner at 90 min (Table 3).
STZ Induced diabetes model
Effect of BR extract on fasting blood glucose level
Administration of the BR extract to STZ induced
diabetic rats caused a significant reduction in fasting
serum glucose (FSG) at level in the doses of 250 and
500 mg/kg. Reduction in FSG level was dose dependent,
i.e. 134.70 mg/dl for BR-2 and 143.88 mg/dl for BR-1 as
revealed on day 28th. Weekly change in FSG level of dif-
ferent dose groups and its comparison with the diabetic
control group has been summarized in the Table 4.
Effect of BR extract on insulin level in diabetic rats
Insulin level was measured on day 1 was considered as
initial reading and finally on day 28 as a final reading.
BR extract caused a significant rise in the level of insulin
in STZ induced diabetic rats. Insulin level was found to
be 0.49 mg/dl for BR-2 extract on day 28 which was
closer to the reference group i.e. glibenclamide
(0.58 mg/dl). Effect of the BR extract on insulin level of
Table 1 In vitro toxicity of BR extract on 3T3-L1 cell lines
Group % Viability
Concentration (μg/ml)
25 50 100 200
DE 93.33 ± 0.84 88.00 ± 0.73 83.33 ± 0.71 79.00 ± 0.25
LE 91.33 ± 1.11 85.00 ± 1.06 80.16 ± 0.60 76.66 ± 0.66
LE = BR extract evaluated under UV light, DE = BR extract evaluated in dark
condition. Values are expressed as mean ± SEM (Number of experiments = 6)
significantly different at *p < 0.05, **P < 0.01, ***P < 0.001
Table 2 Antiadipogenic activity of BR extract on 3T3-L1 cell
Lines
S. N. Group % Inhibition
Concentration (μg/ml)
50 100 200
1. LE 20.66 ± 1.28 31.16 ± 1.47 39.33 ± 0.88
2. DE 23.16 ± 0.65 33.83 ± 1.32 41.66 ± 1.05
3. Simvastatin 32.50 ± 1.36 41.33 ± 0.49 51.83 ± 1.85
LE = BR extract evaluated under UV light (Light extract), DE = BR extract
evaluated in dark condition (Dark extract)
Values are expressed as mean ± SEM (Number of experiments = 6) significantly
different at *p < 0.05, **P < 0.01, ***P < 0.001
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STZ induced diabetic rats is graphically summarized in
Fig. 3.
Effect of BR extract on lipid profile in diabetic rats
STZ-induced diabetic rats having an increased amount
of cholesterol, LDL and triglyceride as compared to their
respective values in control animals. Administration of
glibenclamide and BR-2 extract caused a significant
reduction in the lipid profile of diabetic rats, i.e.
53.75 mg/dl and 57.66 mg/dl respectively. BR-2 extract
exhibited an increase in the level of HDL (52.74 mg/dl)
with a decrease in TG (87.34 mg/dl) and TC
(117.38 mg/dl) levels. Lipid profile of STZ-induced
diabetic rats has been summarized in Table 5.
Effect of BR extract on body weight of diabetic rats
STZ caused an abrupt decrease in body weight of
animals. However treatment of diabetic animals with BR
extract revealed a significant rise in body weight in a
weekly pattern and the results were closer to the refer-
ence group animals (Fig. 4). At the end of the study on
day 28 the body weight of BR-2 treated animals was
found to be 183.48 gm which was equal to reference
group animals i.e. 184.31 gm.
Discussion
This study suggested that BR possess definite antidia-
betic, hypolipidemic and antiadipogenic activity in
STZ-induced diabetic rats. BR extract showed a dose
dependent fall in FSG with 250 and 500 mg/kg dose
in experimental diabetic animals. Moreover, the daily
administration of the BR extract to STZ-diabetic rats
for four weeks caused a significant reduction in food
and water intakes, and an increase in the body
weight. STZ is a cytotoxic compound which induces
Fig. 2 Effect of BR extract on 18 h fasted Wistar rats. NC = Normal control, RG = Reference group (glibenclamide), BR-1 = BR extract in dose of
250 mg/kg, BR-2 = BR extract in dose of 500 mg/kg. Values are expressed as mean ± SEM (Number of animals, n = 6); significantly different at,
*p < 0.05, **P < 0.01, ***P < 0.001 when compared to control group at 0 h blood glucose level
Table 3 Effect of BR extract on blood glucose level of glucose primed rats
S. N. Group Dose (mg/kg) Blood Glucose Level (mg/dl)
0 min 30 min# 90 min#
1. NC Untreated 77.71 ± 0.87 78.02 ± 0.79 78.68 ± 1.13
2. GPC Vehicle 81.32 ± 1.08 172.91 ± 1.85*** 178.65 ± 1.13***
3. RG + glucose 5.0 79.34 ± 0.80 152.87 ± 2.12*** 90.44 ± 2.42***
4. BR-1+ glucose 250 82.30 ± 1.15 157.78 ± 2.45*** 123.57 ± 3.49***
5. BR-2+ glucose 500 81.97 ± 1.04 152.92 ± 1.02*** 115.65 ± 1.45***
#Time post glucose administration. NC = Normal control, GPC = glucose primed control, RG = Reference group (glibenclamide), BR-1 = BR extract in dose of
250 mg/kg, BR-2 = BR extract in dose of 500 mg/kg
Values are expressed as mean ± SEM (Number of animals = 6) significantly different at *p < 0.05, **p < 0.01, ***p < 0.001
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diabetes by damaging β pancreatic cells that causes a
reduction in insulin release. [25], reported that ex-
tracts of medicinal plants causes activation of β cells
as an antidiabetic effect and hence showing insulino-
genic action. STZ causes persistent hyperglycemia
through destruction of pancreatic β-cells (type-I dia-
betes mellitus). The possible mechanism through
which BR extracts showed an antidiabetic effect might
have been due to increased utilization of glucose by
peripheral tissues, improved sensitivity of target tis-
sues for insulin or it may be due to β-cell stimula-
tion. Extract of BR exhibited hypocholesterolemic and
hypotriglyceridemic effects, while increasing the levels
of HDL in diabetic rats. These findings have been
well justified by various reports in the literature stat-
ing that some medicinal plants show antidiabetic as
well as hypolipidemic effects [26].
The elevation of serum insulin in BR extract treated
STZ-induced diabetic rats could either be due to the
insulinotropic substances present in the extract, which
induce the intact functional β-cells to produce insulin,
or the protection of the functional β-cells from
further deterioration so that they remain active and
produce insulin. Similarly the extracts of Medicago
sativa [27], Eucalyptus globulus [25, 28] and Sambu-
cus nigra [29] have been reported to possess antidia-
betic property by insulin-releasing action. Since
insulin inhibits the activity of Glc-6-Pase in the liver
of diabetic rats and controls hepatic glucose production
(HGP), the insulinotropic effect of BR might play an im-
mense role in the control of diabetes in STZ-induced dia-
betic rats. The suppression of Glc-6-P hydrolysis could
also be one of the reasons for the hypoglycemic effect of
the BR extract in diabetic rats. The improvement in lipid
Table 4 Effect of BR extract on STZ induced diabetes in rats
S. N. Group Dose (mg/kg) Blood Glucose Level (mg/dL)
Day 0 Day 7 Day 14 Day 21 Day 28
NC untreated 79.12 ± 0.78 89.83 ± 1.10 86.36 ± 1.03 87.60 ± 1.43 87.46 ± 2.37
DC vehicle 80.20 ± 0.56 370.04 ± 6.28 338.30 ± 13.18 297.97 ± 2.66 297.76 ± 2.97
RG 5.0 81.35 ± 0.49 353.33 ± 3.49** 261.48 ± 2.69*** 182.82 ± 3.18*** 122.70 ± 3.26***
BR-1 250 81.37 ± 0.47 361.00 ± 2.80 281.10 ± 2.55*** 204.49 ± 3.79*** 143.88 ± 2.06***
BR-2 500 79.72 ± 0.74 355.41 ± 3.17* 264.23 ± 2.56*** 191.24 ± 2.69*** 134.70 ± 1.58***
NC = Normal control, DC = Diabetic control, RG = Reference group (glibenclamide), BR-1 = BR extract in dose of 250 mg/kg, BR-2 = BR extract in dose of 500 mg/kg
Values are expressed as mean ± SEM (Number of animals = 6) significantly different at *p < 0.05, **p < 0.01, ***p < 0.001
Fig. 3 Effect of BR extract on Insulin Level of STZ induce diabetes rats. NC =Normal control, DC =Diabetic control, RG = Reference group (glibenclamide),
BR-1 = BR extract in dose of 250 mg/kg, BR-2 = BR extract in dose of 500 mg/kg. Values are expressed as mean ± SEM (Number of animals, n= 6);
significantly different at, *p< 0.05, **p< 0.01, ***p< 0.001 when compared with diabetic control group
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profile by these extracts also supports their antidiabetic
activity along with antihyperlipidemic activity [30].
BR extract showed more than 75% of viability of
cells during in-vitro study. The extract of BR revealed
significant inhibition in differentiated cell as compared to
non-differentiated cell in 3T3-L1 cell line [31]. Improve-
ment in lipid profile reduces the possibilities of diabetes
induced obesity and cardiovascular diseases [32]. BR
extract normalized the amount of triglycerides (TG)
and total cholesterol (TC) in STZ-induced diabetic
rats and may be effective for the treatment of cardio-
vascular disease like coronary artery disease, athero-
sclerosis etc. Triglycerides (TG) are prepared from
carbohydrates as a major energy source or derived from
fats, by taking food [33]. Calories present in food is not
absorbed immediately by tissues; it is converted into TG
and transported to fat cells for storage. Release of triglyc-
erides from fat tissues is regulated by hormones to meet
the body’s needs for energy between meals. Excess
triglycerides in plasma are called hypertriglyceridemia.
Elevation in triglyceride level may be a consequence of an-
other disease like untreated diabetes mellitus. STZ-
induced diabetes and adipocyte differentiation assay have
been used as a model to evaluate the effect of test prod-
ucts on lipid/fat metabolism [34, 35]. To develop the anti-
diabetic drugs and antiadipogenic drugs the lipid centric
approach has been widely used.
Conclusion
It is revealed from the present study that BR extract pos-
sess antidiabetic activity due to decreasing blood glucose
level of STZ-induced diabetic rats. Furthemore, BR ex-
tract also exhibits lowering effect on lipid level and adi-
pose tissue. Due to this property the extract showed
significant antiadipogenic and hypolipidemic effect.
Pharmacologically, the extract improved the lipid profile
by decreasing the levels of serum triglycerides, total
cholesterol, LDL and increasing HDL cholesterol.
Table 5 Effect of BR extract on Lipid profile of STZ induced diabetes in rats
S. N. Group Dose (mg/kg) Lipid profile (mg/dL)
TG TC HDL LDL
1 NC Untreated 88.90 ± 0.92 97.08 ± 1.003 57.37 ± 0.57 47.52 ± 0.57
2 DC Vehicle 106.47 ± 2.12 148.91 ± 0.80 33.39 ± 1.27 105.16 ± 3.61
3 RG 5.0 85.88 ± 0.34*** 106.00 ± 0.40*** 57.30 ± 0.65*** 53.75 ± 0.78***
4 BR-1 250 89.84 ± 0.78*** 126.29 ± 1.37*** 45.14 ± 1.32*** 60.14 ± 1.31***
5 BR-2 500 87.34 ± 0.77*** 117.38 ± 0.75*** 52.74 ± 0.44*** 57.66 ± 1.21***
NC = Normal control, DC = Diabetic control, RG = Reference group (glibenclamide), BR-1 = BR extract in dose of 250 mg/kg, BR-2 = BR extract in dose of 500 mg/kg
Values are expressed as mean ± SEM (Number of animals = 6) significantly different at *p < 0.05, **p < 0.01, ***p < 0.001
Fig. 4 Effect of BR extract on body weight of diabetic rats. NC = Normal control, DC = Diabetic control, RG = Reference group (glibenclamide),
BR-1 = BR extract in dose of 250 mg/kg, BR-2 = BR extract in dose of 500 mg/kg. Values are expressed in mean ± S.E.M. Where n = 6, *p < 0.05,
**p < 0.01, ***p < 0.001; compared with diabetic control group
Kumar et al. Clinical Phytoscience  (2017) 3:7 Page 8 of 9
Conclusively, these effects of BR may be useful for the
development of potent herbal medicine for diabetes. The
relevance of anti-obesity mechanism of BR extractmay
be more appropriate. Further studies to isolate, identify
and characterize the active principle(s) are in progress.
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